QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 11/2/183    most recent 15228517-2008-076v1 Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kozak, K. R. Articles by Moody, J. S. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI (K.R.K.), Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA (A.M.), Department of Radiation Oncology, University of Alabama School of Medicine, Birmingham, AL, (J.S.M.); USA

Address correspondence to Kevin R. Kozak, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4/362 CSC, 600 Highland Ave., Madison, WI 53792, USA (kozak{at}humonc.wisc.edu).

The epidemiology and natural history of adult gliosarcomas (GSMs), as well as patient and treatment factors associated with outcome, are ill defined. Patients over 20 years of age with GSM diagnosed from 1988 to 2004 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival analysis and Cox models were used to examine outcomes. Similar analyses were conducted for patients diagnosed with glioblastoma (GBM) over the same time period. GSM represented 2.2% of the 16,388 patients identified with either GSM or GBM. No significant differences between GSM and GBM were identified with respect to age, gender, race, tumor size, or use of adjuvant radiation therapy (RT). Patients with GSM were more likely to have temporal lobe involvement and undergo some form of tumor resection. The most important analyzed factors influencing GSM overall survival were age, extent of resection, and use of adjuvant RT. After adjusting for factors impacting overall survival, the prognosis for GSM appears slightly worse than for GBM (HR = 1.17, 95% CI, 1.05–1.31). GSM is a rare malignancy that presents very similarly to GBM with a slightly greater propensity for temporal lobe involvement. Optimal treatment remains to be defined. However, these retrospective findings suggest tumor excision, as opposed to biopsy only, and adjuvant RT may improve outcome. Despite therapy, prognosis remains dismal and outcomes may be inferior to those seen in GBM patients.

Key Words: glioblastoma • gliosarcoma • radiation • SEER

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?